Ovarian cancer is the fourth most common cancer in the UK, affecting approximately 6,500 women each year. Diagnosis tends to happen at the later stages of the disease when treatment options are limited but detecting it earlier would greatly improve the chances of effective treatment.
Some biomarkers for ovarian cancer exist, but their reliability for correct diagnosis varies. Thus, the need remains to identify a robust biomarker that can be used to screen patients non-invasively and ideally detect ovarian cancer early
There’s currently a lack of early-stage models for the disease, with most mouse ‘models’ mimicking aggressive, late-stage forms. Furthermore, most cell lines available for research have been produced using a variety of cell types, even though 80% of all ovarian cancers develop from fallopian tube epithelial cells.